New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation.

Annual Review of Medicine
Aliza Hussain, Christie M Ballantyne

Abstract

Although numerous trials have convincingly shown benefits of statin therapy in both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), most showed relative risk reductions of 25-40%, and thus many individuals continue to have ASCVD events despite statin therapy. Substantial progress has been made in developing therapies that address the residual risk for ASCVD despite statin therapy. In this review, we summarize progress of currently available therapies along with therapies under development that further reduce low-density lipoprotein cholesterol and apolipoprotein B-containing lipoproteins, reduce lipoprotein(a), reduce ASCVD events in patients with high triglycerides, and directly target inflammation to reduce ASCVD risk.

References

Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jul 3, 2008·Journal of Lipid Research·Claes BergmarkSotirios Tsimikas
Jul 15, 2009·British Journal of Pharmacology·Payal Kohli, Bruce D Levy
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Dec 26, 2012·Journal of the American College of Cardiology·Stefan M NidorfPeter L Thompson
Jan 18, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Harold E BaysParesh N Soni
Jun 19, 2014·The New England Journal of Medicine·Anders Berg JørgensenAnne Tybjærg-Hansen
Dec 2, 2014·Journal of the American Chemical Society·Jayaprakash K NairMuthiah Manoharan
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Nov 29, 2016·Nature Communications·Stephen L PinkoskyNarendra D Lalwani
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Apr 8, 2017·Journal of the American College of Cardiology·Nathan O StitzielUNKNOWN PROMIS and Myocardial Infarction Genetics Consortium Investigators
May 26, 2017·The New England Journal of Medicine·Mark J GrahamSotirios Tsimikas
May 26, 2017·The New England Journal of Medicine·Frederick E DeweyAris Baras
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Mar 14, 2018·Circulation·Erin A BohulaMarc S Sabatine
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Nov 13, 2018·The New England Journal of Medicine·Paul M RidkerUNKNOWN CIRT Investigators
Nov 18, 2018·The New England Journal of Medicine·John J P Kastelein, Erik S G Stroes
Dec 28, 2018·Circulation·Michelle L O'DonoghueMarc S Sabatine
Mar 14, 2019·The New England Journal of Medicine·Kausik K RayUNKNOWN CLEAR Harmony Trial
Mar 16, 2019·Frontiers in Cardiovascular Medicine·Aaron W Aday, Paul M Ridker
Mar 23, 2019·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN REDUCE-IT Investigators
Mar 23, 2019·Journal of the American College of Cardiology·J Wouter JukemaUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Jul 23, 2019·European Heart Journal·Veronica J AlexanderSotirios Tsimikas
Aug 8, 2019·The New England Journal of Medicine·Joseph L WitztumEric Bruckert
Aug 31, 2019·Journal of the American College of Cardiology·Shaun G GoodmanUNKNOWN ODYSSEY OUTCOMES Committees and Investigators

❮ Previous
Next ❯

Citations

Aug 8, 2021·Genetics in Medicine : Official Journal of the American College of Medical Genetics·David R MurdockRichard A Gibbs

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.